FDA’s NAM framework emphasizes context of use, human biological relevance, technical characterization, and fit-for-purpose ...
Last week, FDA issued the final version of its 2023 revised draft guidance, “Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations: Questions and Answers,” which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results